Trials Sponsors Conditions Drugs Pricing

Conditions

Hematuria-Nephropathy-Deafness Syndrome Nephritis, Hereditary

Keywords

Alport SyndromeBiomarker

Outcome Measures

Primary Outcomes (1)

Identification of Alport Syndrome biomarker/s
All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.
36 months

Secondary Outcomes (1)

Exploring the clinical robustness, specificity, and long-term variability of Alport syndrome biomarker/s
36 months

Study Arms (1)

Participants with Alport Syndrome

Participants diagnosed with Alport syndrome aged between 2 months and 50 years

Eligibility Criteria

Age2 Months - 50 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

Participants with Alport Syndrome

You may qualify if:

Informed consent is obtained from the participant or the parent/ legal guardian.

Sponsors & Collaborators

CENTOGENE GmbH Rostock
Industrylead

Study Sites (7)

University Hospital Center Mother Teresa

Tirana, 10001, Albania

Department of Molecular and Medical Genetics, Tbilisi State Medical University

Tbilisi, 0177, Georgia

Amrita Institute of Medical Sciences & Research Centre

Kochi, Kerala, 682041, India

Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos

Vilnius, 08406, Lithuania

Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health

Lahore, 54600, Pakistan

Emergency Hospital for Children "Louis Turcanu"

Timișoara, 300011, Romania

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)

MeSH Terms

Conditions

Nephritis, Hereditary

Condition Hierarchy (Ancestors)

Urogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesNephritisKidney DiseasesUrologic DiseasesMale Urogenital DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCollagen DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

Peter Bauer, Prof. Dr.
Centogene GmbH
STUDY CHAIR

Enrollment

12 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 10, 2015

First Posted

March 24, 2016

Study Start

August 20, 2018

Actual (reported)

Study Stopped

Biomarker for Alport Syndrome (BioAlport)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Participants with Alport Syndrome

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (7)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Participants with Alport Syndrome

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (7)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations